Overview of the drug development pipeline for ankylosing spondylitis
Ankylosing spondylitis can be defined as a type of arthritis that affects the joints of the spine and causes inflammation of spinal joints. Patients suffering from this condition experience severe discomfort and chronic pain. This condition also affects other areas of the body such as heels, small joints of hands and feet, ribs, shoulders, and hips. In addition, the progression of this disease can affect the mobility of the patient by causing abnormal joining of bones or fused vertebrae and overgrowth of bones. Technavio’s market research analysts have predicted that with the introduction of medications, therapy, and surgery as some of the most promising investigational approaches to treat ankylosing spondylitis, the ankylosing spondylitis market size will increase in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are being produced under the phase II drug development stage. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under pre-clinical, phase III, and discovery stage.
Ankylosing spondylitis market forecast: Companies covered
Based on the ankylosing spondylitis industry analysis, this pipeline report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of for ankylosing spondylitis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- BIOCAD
- AbbVie
- UCB Pharma
Therapeutic assessment of the drug development pipeline for ankylosing spondylitis by route of administration
- Oral
- Intravenous
- Subcutaneous
The subcutaneous route of administration (ROA) involves the administration of drug substances directly into the tissue layer between the skin and the muscle with a short needle. It has been observed that the majority of total therapeutics are being developed for subcutaneous administration.
Therapeutic assessment of the drug development pipeline for ankylosing spondylitis by therapeutic modalities
- Small molecules
- Biological molecules
According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for ankylosing spondylitis are being developed as a biological molecule. Biological molecules include macro-molecules or polyanions such as proteins, starches, lipids, and nucleic acid. They also include small molecules such as essential metabolites, auxiliary metabolites, and regular items.
Key questions answered in the report include
- What are the drug development molecules in the various development stages for ankylosing spondylitis?
- What are the companies that are currently involved in the development of drug molecules for ankylosing spondylitis?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.